Idorsia cuts development costs in updated Viatris deal

Swiss biotech company Idorsia (SIX: IDIA) has revised its collaboration terms with Viatris (Nasdaq: VTRS), reducing its financial commitment to the development of two late-stage drugs. In exchange, the company has accepted a significant reduction in future potential earnings.

Idorsia will now contribute a total of $100 million toward the development of selatogrel and cenerimod, down from an original commitment of $200 million. 

The company has already paid $73 million of this amount, with the remaining $27 million set to be paid in four quarterly installments in 2026. In return, Idorsia’s potential future regulatory and sales milestone payments from Viatris will be reduced by $250 million.